Company news from the 04/28/06 News Brief

Share this article:
Cytogen Corporation and Savient Pharmaceuticals reached a distribution agreement granting Cytogen exclusive marketing rights for Soltamox (tamoxifen citrate) in the US. Financial terms of the agreement were not disclosed. Soltamox, a cytostatic estrogen receptor antagonist, is the first oral liquid hormonal therapy approved in the US. It is indicated for the treatment of breast cancer in adjuvant and metastatic settings and to reduce the risk of breast cancer in women with ductal carcinoma in situ (DCIS) or with high risk of breast cancer.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.